CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

Slides:



Advertisements
Similar presentations
Investigator Responsibilities in Clinical Research
Advertisements

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
AUDIT PROGRAM Tammy Neseth NCCTG Compliance Coordinator.
Quality Management within the Clinical Research Process
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
© Clinical Research Practice Clinical Research Organization and Management 1.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Capturing and Reporting Adverse Events in Clinical Research
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Cancer Clinical Trials:
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Auditing & Quality Assurance Igor Espinoza-Delgado, M.D. Gary Smith M.Sc. Cancer Therapy Evaluation Program.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
1 Investigating Fraud & Abuse Violations in Medical Research Janet Rehnquist, Esq. Venable LLP th Street, NW Washington, DC
Read the SMALL PRINT of the 1572 The Essential GCP Document.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CTMB Guidelines (Rev. October 2006) Section 5: Conducting the Quality Assurance Audit.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
UNIT-II CLINICAL DATA. UNIT-II CLINICAL DATA: Clinical Data, Application, Challenges, Solutions, Clinical Data Management System.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Responsibilities of Sponsor, Investigator and Monitor
Bozeman Health Clinical Research
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reporting to the CPHS: Unanticipated Problems & Serious Adverse Events
Understanding the Process of Documenting Informed Consent
Quality Assurance in Clinical Trials
Presentation transcript:

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee

AGENDA David HurdIntroduction Trinidad AjaziTransition Barbara BarrettSignificance Questions & Answer Period

How did we get here?? National Cancer Institute The world’s largest sponsor of clinical trials of investigational anti-neoplastic agents and cancer clinical trials. NCI must ensure that the research data generated under its sponsorship are High Quality Reliable Verifiable

How did we get here?? 1955 Monitoring policies for Clinical Trials have been in evolution since the start of the Clinical Trials Cooperative Group Program 1963 Harris-Kefauver amendments to the Food, Drug, and Cosmetic Act required the FDA to oversee investigational new drug (IND) testing in humans subjects 1977 FDA published proposed regulations on Responsibilities of sponsors and monitors of clinical trials “Annual site visit of each investigator” Most sponsors conform to these proposals

How did we get here?? 1982 NCI made on-site monitoring a requirement for Clinical Trials Cooperative Group Program Cancer Centers Community Clinical Oncology Program (CCOP) Other investigators conducting clinical trials under its sponsorship NCI delegated much of the responsibility for on-site monitoring of investigational agents and clinical trials to the Cooperative Groups

FDA regulations require Division of Cancer Treatment and Diagnosis (DCTD) to maintain a monitoring program Clinical Trials Monitoring Branch (CTMB) of the Cancer Therapy Evaluation Program (CTEP) CTMB - provides direct oversight of each Cooperative Group’s monitoring program which includes auditing as one component

Clinical Trials Monitoring Branch Purpose of Audit To document the accuracy of data submitted to the Cooperative Groups To verify investigator compliance with protocol requirements To verify investigator compliance with regulatory requirements To provide an opportunity for the audit team to share with the institution staff Information concerning data quality Information concerning data management Other information on the aspects of quality assurance

AUDIT Could/Should = Educational Process Audit team members should share practices that have been successfully implemented at other institutions Clinical practice techniques Data management systems Quality control systems Goal of the local staff Use the results of the on-site audit to identify operational areas where improvements could be made

Why Do Audits?? Investigators of clinical trials have an obligation to take appropriate steps To protect human subjects who participate in research studies To protect the integrity of the science

Why Do Audits?? The integrity of a data set is a function of the entire process Data collection Data analysis Detailed plans and systems are needed to assure Protocol adherence Uniform collection of data

Why Do Audits?? Detect honest errors systemic or random Detect falsification hopefully rare event, however….

Breast Cancer Clinical Trials Bezwoda et al: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995, 13: “[High dose chemotherapy]…results in a significant proportion of CRs and increased survival in patients with metastatic breast cancer” Weiss RB, et al: An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 2001; 19: “the multiple publications of this study to not report verifiable data, and 9 other publications co-authored by the principal investigator contain at least one major untrue statement”

Cancer researcher admits falsifying trial results Trial results presented at ASCO’s annual meeting misrepresented treatment in the control group The University of Witwatersrand Medical School Investigated Werner Bezwoda, MD, PhD for scientific misconduct for allegedly lying about the results of a clinical trial on high-dose chemotherapy and stem cell support for breast cancer Bezwoda in a document sent to his colleagues: Acknowledged that he committed a serious breach of scientific honesty and integrity by misrepresenting the results of that trial Resigned his position at the university

Other Examples A CRA at a US Hospital was found guilty of falsifying the data in the study records of 35 men on the SWOG SELECT trial for prostate cancer prevention Drug Company Study of a toxicity protectant The CRAs at 4 different institutions falsified at least one QOL document that was to be completed by the participant Three CRAs completed the form and signed the participant’s signature One CRA used one form signed by the participant, changed the date with white-out, and submitted it as the form for a later date

Data Audit = Quality Assurance Dr. Curtis Meinert defines QA as Any method or procedure for collecting, processing, or analyzing study data that is aimed at Maintaining or enhancing their reliability and validity Includes prevention, detection, and action from the beginning of data collection through publication of the results to assure Unbiased treatment assignment Adequate assessment of eligibility Compliance with protocol treatment Compliance with regulatory requirements Complete collection of data on the primary outcome measures

Why do we do audits? To assure all patient protection measures are followed To educate all involved in clinical trials research regarding protocol adherence and data collection To find and correct errors To assure all pharmacy procedures are followed To help provide assurance the study results are valid To discourage fraud and find its rare instances, and finally BECAUSE WE HAVE TO!!!!!!!!!!!!!!!!